Your Article Summary
See Latest ArticlesFrequency Distribution of Second Solid Cancer Locations in Relation to the Irradiated Volume Among 115 Patients Treated for Childhood Cancer
International Journal of Radiation Oncology*Biology*Physics, 06/24/09
Diallo I et al. - A greater volume of tissues receives low or intermediate doses in regions bordering the irradiated volume with modern multiple-beam RT arrangements. These results should be considered for risk–benefit evaluations of RT.
Related Articles
Childhood Cancer Survivors Experience Suicidal Thoughts Decades After Diagnosis
ScienceDaily, 10/27/09
Relevance Score: 71%
Childhood cancer mortality in Europe, 1970–2007
European Journal of Cancer, 10/14/09
Relevance Score: 70%
Survivors Of Childhood Cancer Less Likely To Marry
ScienceDaily, 10/09/09
Relevance Score: 70%
Childhood cancer survivors less likely to marry
EurekAlert, 11/03/09
Relevance Score: 69%
Thyroid cancer a risk after childhood cancer
Reuters, 10/28/09
Relevance Score: 69%
Today in Pediatric Heme/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Current Approach to Pediatric Soft Tissue Sarcomas
The Oncologist, 12/02/09
Frequency and prognostic significance of murine double minute protein-2 overexpression and p53 gene mutations in childhood acute lymphoblastic leukemia
Hematology, 12/02/09
Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical Effects
Journal of Clinical Oncology, 11/24/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole
Breast Cancer Research and Treatment, 12/02/09
A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action
Breast Cancer Research and Treatment, 12/02/09
FDA Drug Approval Summary: Bevacizumab (Avastin) as Treatment of Recurrent Glioblastoma Multiforme
The Oncologist, 12/02/09